|
Match
|
Document |
Document Title |
|
|
7601700 |
Modulation of eIF4E expression
Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid...
|
|
|
7601696 |
Oct-1 as an oncoprotein and use of nucleic acid inhibitors of Oct-1 for cancer treatment
Oct-1 is shown to be an oncoprotein because of its known role as an activator of the histone H2B gene and the importance of this gene during DNA synthesis. To determine the role of Oct-1 as an...
|
|
|
7598369 |
siRNA targeting histamine receptor H1
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene...
|
|
|
7598370 |
siRNA targeting polo-like kinase-1 (PLK-1)
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene...
|
|
|
7595389 |
siRNA targeting casitas B cell lymphoma-B (CBL-B)
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene...
|
|
|
7595301 |
Staple type oligonucleotide and drug comprising the same
Conventional oligonucleotides are opened at both ends and thereby unstable. Their stability against catabolic enzymes is increased by phosphorothioate modification, but such phosphorothioate causes...
|
|
|
7595388 |
siRNA targeting EPH receptor A3 (EPHA3)
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene...
|
|
|
7595306 |
Method of treating neurodegenerative disease
Aspects featured in the invention relate to compositions and methods for inhibiting alpha-synuclein (SNCA) gene expression, such as for the treatment of neurodegenerative disorders. An anti-SNCA...
|
|
|
7595304 |
Polymeric oligonucleotide prodrugs
Polymer conjugates containing nucleotides and/or oligonucleotides are disclosed.
|
|
|
7595387 |
Modified polynucleotides for reducing off-target effects in RNA interference
Methods and compositions for performing RNA interference with decreased off-target effects are provided The methods and compositions permit effective and efficient applications of RNA interference...
|
|
|
7595386 |
Methods and compositions for heat activated gene therapy using cytolethal distending toxin
The invention provides compositions and methods for gene therapy using cytolethal distending toxins (CDTs). In a preferred embodiment, a gene therapy vector according to the invention includes a...
|
|
|
7592322 |
RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
The present invention is based on the in vivo demonstration that RSV and PIV can be inhibited through intranasal administration of RNAi agents as well as by parenteral administration of such...
|
|
|
7592446 |
Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids
The present invention provides selenium derivatives of nucleosides, nucleoside phosphoramidites, nucleotides, nucleotide triphosphates, oligonucleotides, polynucleotides, and larger nucleic acids...
|
|
|
7592442 |
siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene...
|
|
|
7592444 |
siRNA targeting myeloid cell leukemia sequence 1
Efficient sequence specific gene silencing of myeloid cell leukemia sequence 1 is possible through the use of siRNA technology. By selecting particular siRNAs directed to myeloid cell leukemia...
|
|
|
7592323 |
TRPM-2 antisense therapy
It has now been determined that antisense therapy which reduces the expression of TRPM-2 provides therapeutic benefits in the treatment of cancer. In particular, such antisense therapy can be...
|
|
|
7592319 |
Uses of DNA-PK
This invention provides a method for increasing the susceptibility of a cell to DNA-damaging agents, comprising introducing into the cell an antisense oligonucleotide that specifically hybridizes...
|
|
|
7592441 |
Liver cancer-related nucleic acids
Described herein are novel polynucleotides associated with liver cancer. The polynucleotides are miRNAs, miRNA precursors, and associated nucleic acids. Methods and compositions are described that...
|
|
|
7592505 |
UDP-xylose synthases (UXS) polynucleotides, polypeptides, and uses thereof
The present disclosure concerns methods and compositions relating to UXS polypeptides and/or nucleic acids encoding UXS polypeptides. In certain claims, the methods and compositions are of use to...
|
|
|
7592443 |
siRNA targeting interleukin-1 receptor-associated kinase 4 (IRAK4)
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene...
|
|
|
7592324 |
RNAi-mediated inhibition of ocular targets
RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension....
|
|
|
7592318 |
88kDa tumorigenic growth factor and antagonists
This invention relates to products and methods for treating cancer and for diagnosing tumorigenicity and other diseases associated with alteration in GP88 expression or action. Antagonists to an 88...
|
|
|
7592440 |
Methods of obtaining active antisense compounds
Methods for obtaining antisense oligonucleotides with activity against a desired target are provided. Methods of identifying oligonucleotide sequence motifs which are predictive of antisense...
|
|
|
7589189 |
Inhibition of the expression of huntingtin gene
It is intended to provide methods for suppressing the huntington gene expression by using a double-stranded RNA (dsRNA), huntington gene expression inhibitors to suppress the huntington gene...
|
|
|
7589191 |
siRNA targeting hypoxia-inducible factor 1
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene...
|
|
|
7589190 |
Potent LNA oligonucleotides for the inhibition of HIF-1A expression
The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5′-( T x )G x G x c s a s a s g s c s a s t s c s c s T x G x T-3′ and...
|
|
|
7589074 |
Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
A method for treating inflammatory joint diseases by inhibiting cadherin-11 mediated cellular function using a cadherin-11 modulating agent is provided. Also provided are screening assays for...
|
|
|
7585966 |
Inhibitory polynucleotides directed against the RNA component of telomerase
This invention provides inhibitory polynucleotides, such as antisense molecules, directed against accessible regions in the telomerase ribonucleoprotein. The polynucleotides are useful for...
|
|
|
7585969 |
MicroRNA and methods for inhibiting same
The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA. In another embodiment, the invention relates to...
|
|
|
7585967 |
Nucleic acid compounds for inhibiting angiogenesis and tumor growth
In certain embodiments, this present disclosure provides nucleic acid compounds, compositions, and methods for inhibiting Ephrin B2 or EphB4 expression. In certain embodiments, the present...
|
|
|
7585847 |
Immunostimulatory nucleic acids for the treatment of asthma and allergy
The invention involves administration of an immunostimulatory nucleic acid alone or in combination with an asthma/allergy medicament for the treatment or prevention of asthma and allergy in...
|
|
|
7585968 |
Compositions and their uses directed to thymus and activation-regulated chemokine (TARC)
Disclosed herein are compounds, compositions and methods for modulating the expression of TARC in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of...
|
|
|
7585848 |
Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
Described herein are methods and compositions for inhibiting, treating and reversing intervertebral disc disorders using transcription factor inhibitors. In certain embodiments, the transcription...
|
|
|
7582475 |
Vectors and methods for high throughput co-expression
The present invention includes vectors and methods for high throughput co-expression.
|
|
|
7582744 |
Chemically modified oligonucleotides
This invention relates composition and methods for making and using chemically modified oligonucleotides agents for inhibiting gene expression.
|
|
|
7582747 |
siRNA targeting inner centromere protein antigens (INCENP)
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene...
|
|
|
7582746 |
siRNA targeting complement component 3 (C3)
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene...
|
|
|
7582615 |
Antisense antiviral compound and method for treating arenavirus infection
The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Arenaviridae family and in the treatment of a viral infection....
|
|
|
7582745 |
Compositions and methods for inhibiting expression of Nav1.8 gene
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Nav1.8 gene (Nav1.8 gene), comprising an antisense strand having a nucleotide sequence which...
|
|
|
7582741 |
Conditional disruption of dicer1 in cell lines and non-human mammals
The present invention is based, at least in part, on the generation of cells, cell lines and non-human mammals that contain a synthetic conditional allele of the Dicer1 gene. Many of the...
|
|
|
7579146 |
Nucleic acid cloning
The present invention provides an improved system for linking nucleic acids to one another. In particular, the present invention provides techniques for producing DNA product molecules that may be...
|
|
|
7579458 |
siRNA targeting synuclein, alpha (SNCA-1)
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene...
|
|
|
7579456 |
Aptamer therapeutics useful in the treatment of complement-related disorders
The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
|
|
|
7579326 |
Gene switch systems employing regulators with decreased dimerization
Disclosed is a novel inducible expression system characterized by undetectable biological effect in the absence of an inducer, but which exhibits efficient inducibility in the presence of an inducer.
|
|
|
7579457 |
siRNA targeting carbonic anhydrase II
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene...
|
|
|
7579455 |
Oligonucleotide compositions and methods for treating disease including inflammatory conditions
The invention relates to therapeutic antisense oligonucleotides directed against genes coding for phosphodiesterase (PDEs) and the use of these in combination. These antisense oligonucleotides may...
|
|
|
7579329 |
P450RAI-2 (P450 cytochrome 26B), encoding nucleic acid molecules and methods and uses thereof
The present invention provides a novel all-trans-RA inducible all-trans-RA metabolizing cytochrome P450, P450RAI-2, that is predominantly expressed in the brain, cerebellum in particular. It is...
|
|
|
7576197 |
SiRNA targeting KRAS
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs directed to silencing KRAS, one can maximize the generation of an...
|
|
|
7576196 |
siRNA targeting transducin (beta)-like 3 (TBL3)
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene...
|
|
|
7576067 |
Pulsatile release compositions and methods for enhanced intestinal oligonucleotide drug absorption
Delayed release oral pharmaceutical formulations and methods for enhanced intestinal drug absorption. The formulation comprises a first population of carrier particles comprising a drug and a...
|